218 filings
Page 2 of 11
8-K
yuinfw 2hjwcoy1
27 Jul 23
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
7:27am
8-K
of2syg3215
13 Jun 23
Departure of Directors or Certain Officers
4:35pm
8-K
zkypnh2fp
11 May 23
Optinose Reports First Quarter 2023 Financial Results
7:10am
8-K
7tsqu
4 May 23
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
7:04am
PRE 14A
6wpn6c70c94rfwf2l5ml
21 Apr 23
Preliminary proxy
4:51pm
8-K
sra2sq
17 Apr 23
Regulation FD Disclosure
8:03am
8-K
mi9ujzen
28 Mar 23
Departure of Directors or Certain Officers
5:27pm
S-8
qucto3 f1v
7 Mar 23
Registration of securities for employees
4:43pm
8-K
78b5vzrcvnauk6 sd
7 Mar 23
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results
7:16am
8-K
lolixv2gxy980
31 Jan 23
Optinose Announces CEO Transition and Business Update
8:06am
8-K
m7zwr
16 Dec 22
Departure of Directors or Certain Officers
4:43pm
8-K
s107 s0v9x
15 Dec 22
Optinose Appoints Paul Spence as Chief Commercial Officer
4:45pm
8-K
lyc96
9 Dec 22
Departure of Directors or Certain Officers
8:02am
8-K
qplxc7q41hnth bsqem
23 Nov 22
Optinose Announces Proposed Public Offering of Common Stock and Warrants
4:09pm
424B5
mj04kpr u1j1hc1d0u2g
23 Nov 22
Prospectus supplement for primary offering
9:37am
424B5
a8uoqbb8sh5xe31owh1
21 Nov 22
Prospectus supplement for primary offering
6:17am
8-K
jn4c uslxq
21 Nov 22
Entry into a Material Definitive Agreement
6:16am